Ignite Creation Date:
2024-05-06 @ 5:10 PM
Last Modification Date:
2024-10-26 @ 2:23 PM
Study NCT ID:
NCT05216432
Status:
RECRUITING
Last Update Posted:
2024-06-06
First Post:
2021-12-20
Brief Title:
First-in-Human Study of Mutant-selective PI3Kα Inhibitor RLY-2608 As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
Sponsor:
Organization:
Relay Therapeutics Inc